Evidence map›Paper›PMID 31448377›Full record

ArticleNanoscale research letters2019

Her2-Functionalized Gold-Nanoshelled Magnetic Hybrid Nanoparticles: a Theranostic Agent for Dual-Modal Imaging and Photothermal Therapy of Breast Cancer.

Qi Dong, Hong Yang, Caifeng Wan, Dongdong Zheng, Zhiguo Zhou, Shaowei Xie, Li Xu, Jing Du, Fenghua Li

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nanoscale research letters, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
4.0field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 66 citations in OpenAlex.

  1. Review
  2. UltrasensitiveAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Enhanced US/CT/MR imaging of integrin αFrontiers in chemistry · 2022
    Article
  12. Nanoparticle Systems for Cancer Phototherapy: An Overview.Nanomaterials (Basel, Switzerland) · 2021
    Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Qi DongDepartment of Ultrasound, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200127, China.
Hong YangDepartment of Chemistry, College of Life and Environmental Science, Shanghai Normal University, Shanghai, 200234, China.
Caifeng WanDepartment of Ultrasound, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200127, China.
Dongdong ZhengDepartment of Ultrasound, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200127, China.
Zhiguo ZhouDepartment of Chemistry, College of Life and Environmental Science, Shanghai Normal University, Shanghai, 200234, China.
Shaowei XieDepartment of Ultrasound, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200127, China.
Li XuDepartment of Ultrasound, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200127, China.
Jing DuDepartment of Ultrasound, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200127, China. beautydujing@163.com.
Fenghua LiDepartment of Ultrasound, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200127, China. fenghua-li@163.com.ORCID http://orcid.org/0000-0002-3726-5059
Shanghai Jiao Tong University · CNShanghai Normal University · CN

Funding

EPA EP-C-17-015
6 · The paper itself

Abstract

Targeted theranostic platform that integrates multi-modal imaging and therapeutic function is emerging as a promising strategy for earlier detection and precise treatment of cancer. Herein, we designed targeted gold-nanoshelled poly (lactic-co-glycolic acid) (PLGA) magnetic hybrid nanoparticles carrying anti-human epidermal growth factor receptor 2 (Her2) antibodies (Her2-GPH NPs) for dual-modal ultrasound (US)/magnetic resonance (MR) imaging and photothermal therapy of breast cancer. The agent was fabricated by coating gold nanoshell around PLGA nanoparticles co-loaded with perfluorooctyl bromide (PFOB) and superparamagnetic iron oxide nanoparticles (SPIOs), followed by conjugating with anti-Her2 antibodies. Cell-targeting studies demonstrated receptor-mediated specific binding of the agent to Her2-positive human breast cancer SKBR3 cells, and its binding rate was significantly higher than that of Her2-negative cells (P < 0.001). In vitro, the agent had capabilities for contrast-enhanced US imaging as well as T

Indexed as

Anti-Her2 antibodyBreast cancerMagnetic resonance imagingPhotothermal therapyTheranostic agentUltrasound imaging

Identifiers

PMID31448377
PMCPMC6709082
OpenAlexW2969579268

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.